Cipla Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Cipla wird ein jährliches Gewinn- und Umsatzwachstum von 9.2% bzw. 8.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 9.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.4% betragen.

Wichtige Informationen

9.2%

Wachstumsrate der Gewinne

9.1%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	8.2%
Zukünftige Eigenkapitalrendite	14.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	19 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

May 14

Recent updates

Cipla (NSE:CIPLA) Is Increasing Its Dividend To ₹13.00

Jun 06

Cipla's (NSE:CIPLA) Upcoming Dividend Will Be Larger Than Last Year's

May 21

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

May 14

Cipla Limited (NSE:CIPLA) Shares Could Be 34% Above Their Intrinsic Value Estimate

Apr 30

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Mar 23

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Dec 18

Calculating The Fair Value Of Cipla Limited (NSE:CIPLA)

Dec 05

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Oct 27

If You Like EPS Growth Then Check Out Cipla (NSE:CIPLA) Before It's Too Late

Sep 16

Cipla Limited (NSE:CIPLA) Shares Could Be 23% Above Their Intrinsic Value Estimate

Aug 31

It's Unlikely That Cipla Limited's (NSE:CIPLA) CEO Will See A Huge Pay Rise This Year

Aug 18

Gewinn- und Umsatzwachstumsprognosen

NSEI:CIPLA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	322,909	51,819	44,113	57,635	14
3/31/2026	305,722	51,893	40,831	52,671	33
3/31/2025	278,920	46,539	34,209	48,564	34
3/31/2024	254,466	41,216	27,846	41,339	N/A
12/31/2023	251,163	37,082	N/A	N/A	N/A
9/30/2023	243,407	34,532	25,988	37,924	N/A
6/30/2023	235,108	31,112	N/A	N/A	N/A
3/31/2023	225,593	28,019	20,736	32,377	N/A
12/31/2022	222,187	26,383	N/A	N/A	N/A
9/30/2022	218,874	25,660	20,120	29,160	N/A
6/30/2022	216,105	24,884	N/A	N/A	N/A
3/31/2022	217,078	25,168	26,285	33,259	N/A
12/31/2021	210,718	25,681	N/A	N/A	N/A
9/30/2021	207,616	25,876	28,362	37,113	N/A
6/30/2021	202,801	25,417	N/A	N/A	N/A
3/31/2021	191,205	24,049	29,418	37,552	N/A
12/31/2020	188,779	22,374	N/A	N/A	N/A
9/30/2020	180,802	18,403	23,627	31,968	N/A
6/30/2020	174,377	16,462	N/A	N/A	N/A
3/31/2020	170,805	15,465	20,684	30,685	N/A
12/31/2019	171,206	16,678	N/A	N/A	N/A
9/30/2019	167,572	16,489	18,294	25,720	N/A
6/30/2019	163,733	15,546	N/A	N/A	N/A
3/31/2019	163,232	15,277	11,640	16,911	N/A
12/31/2018	155,224	13,391	N/A	N/A	N/A
9/30/2018	154,287	14,074	N/A	N/A	N/A
6/30/2018	154,992	14,530	N/A	N/A	N/A
3/31/2018	151,053	14,105	6,466	14,628	N/A
12/31/2017	147,618	11,701	N/A	N/A	N/A
9/30/2017	144,951	11,444	N/A	N/A	N/A
6/30/2017	141,637	10,762	N/A	N/A	N/A
3/31/2017	143,340	10,064	N/A	23,818	N/A
12/31/2016	142,509	11,213	N/A	N/A	N/A
9/30/2016	137,547	10,071	N/A	N/A	N/A
6/30/2016	134,335	12,219	N/A	N/A	N/A
3/31/2016	135,480	13,600	N/A	17,408	N/A
12/31/2015	135,044	16,847	N/A	N/A	N/A
9/30/2015	131,633	16,694	N/A	N/A	N/A
6/30/2015	124,782	15,368	N/A	N/A	N/A
3/31/2015	113,454	11,808	N/A	11,734	N/A
12/31/2014	106,195	11,818	N/A	N/A	N/A
9/30/2014	105,627	11,383	N/A	N/A	N/A
6/30/2014	104,164	11,976	N/A	N/A	N/A
3/31/2014	101,734	13,884	N/A	15,633	N/A
12/31/2013	94,330	14,042	N/A	N/A	N/A
9/30/2013	89,509	14,602	N/A	N/A	N/A
6/30/2013	86,548	15,901	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CIPLADas prognostizierte Gewinnwachstum (9.2% pro Jahr) liegt über der Sparquote (6.7%).

Ertrag vs. Markt: CIPLADie Erträge des Unternehmens (9.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (16% pro Jahr).

Hohe Wachstumserträge: CIPLADie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: CIPLADie Einnahmen des Unternehmens (8.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (9.6% pro Jahr).

Hohe Wachstumseinnahmen: CIPLADie Einnahmen des Unternehmens (8.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CIPLADie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.3 %).

Cipla Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Price target increased by 8.7% to ₹1,391

Price target increased to ₹1,208

Price target increased to ₹1,202

Consensus forecasts updated

Recent updates

Cipla (NSE:CIPLA) Is Increasing Its Dividend To ₹13.00

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Cipla's (NSE:CIPLA) Upcoming Dividend Will Be Larger Than Last Year's

Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director

Promoter Group Entities Reportedly Likely to Sell 2.5% Stake in Cipla worth INR 26.37 Billion via Block Deals

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Dividend increased to ₹13.00

Cipla Limited, Annual General Meeting, Aug 20, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director

With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case

Cipla Limited to Report Q4, 2024 Results on May 10, 2024

Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024

Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Price target increased by 8.7% to ₹1,391

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson

Third quarter 2024 earnings: EPS exceeds analyst expectations

Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Second quarter 2024 earnings released: EPS: ₹14.01 (vs ₹9.78 in 2Q 2023)

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Cipla Limited to Report Q2, 2024 Results on Oct 27, 2023

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Blackstone Reportedly Withdraws Plan to Acquire Founders' Stake in Cipla

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Cipla's Founding Family's Stake Sale Reportedly in Jeopardy over $13 Billion Valuation Target

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Blackstone Reportedly to Submit Bid for over 33% Stake in Cipla

Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?

Cipla Promoters Reportedly Mull Stake Sale to Top PE Firms Blackstone, Baring Asia

Cipla Limited Announces Change in Management

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited, Annual General Meeting, Aug 10, 2023

Cipla Limited to Report Q1, 2024 Results on Jul 26, 2023

Shibam Group Holding Limited entered into a binding term sheet to acquire additional 51% stake in Saba Investment Ltd from Cipla Limited (NSEI:CIPLA) for $6.5 million.

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited Announces Resignation of Peter Mugyenyi as Independent Director, Effective May 13, 2023

Is Cipla (NSE:CIPLA) A Risky Investment?

A Look At The Fair Value Of Cipla Limited (NSE:CIPLA)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Cipla Limited Announces the Launch of Cippoint

Cipla Limited to Report Q3, 2023 Results on Jan 25, 2023

Cipla (NSE:CIPLA) Has A Pretty Healthy Balance Sheet

Cipla Limited and Cipla Usa Inc. Announces the Launch of Leuprolide Acetate Injection Depot 22.5Mg

Price target increased to ₹1,208

Price target increased to ₹1,202

Second quarter 2023 earnings: EPS exceeds analyst expectations

Cipla Limited to Report Q2, 2023 Results on Nov 04, 2022

Cipla Limited Receives the Establishment Inspection Report Indicating Closure of the Inspection

Cipla Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Cipla Limited (NSEI:CIPLA) agreed to acquire additional 13.10% stake in Jiangsu Acebright Pharmaceutical Co. Limited for USD 16.40 million.

Estimating The Fair Value Of Cipla Limited (NSE:CIPLA)

Cipla Limited Announces Executive Changes

Upcoming dividend of ₹5.00 per share

First quarter 2023 earnings released: EPS: ₹8.51 (vs ₹8.86 in 1Q 2022)

Cipla Limited, Annual General Meeting, Aug 26, 2022

Cipla (NSE:CIPLA) Will Pay A Dividend Of ₹5.00

Cipla Limited Recommends Final Dividend for Fiscal Year 2021-22

Cipla (NSE:CIPLA) Could Easily Take On More Debt

Cipla Limited to Report Q1, 2023 Results on Jul 29, 2022

Cipla Limited Notifies That the United States Food and Drug Administration Conducted A Pre Approval Inspection

If EPS Growth Is Important To You, Cipla (NSE:CIPLA) Presents An Opportunity

Cipla Limited (NSEI:CIPLA) agreed to acquire unknown stake in GoApptiv Private Limited.